Menu Close

Trending

Survival data firms up Trodelvy prospects in new breast cancer use
UK first to approve Moderna’s Omicron booster jab
Evidence-backed VR therapy helps patients overcome phobias
Strike three for Novartis’ canakinumab as lung cancer therapy
Enhertu role in breast cancer confirmed, as Daiichi wins Seagen dispute

Kisqali

NICE1

Market Access/ News/ News

NICE okays regular NHS funding for Novartis’ breast cancer drug Kisqali

, , , , , 0 Comment

NICE has recommended moving Novartis’ Kisqali (ribociclib) from interim funding arrangements to regular NHS reimbursement for certain previously

X
NICE okays regular NHS funding for Novartis’ breast cancer drug Kisqali
https://pharmaphorum.com/news/nice-okays-regular-nhs-funding-for-novartis-breast-cancer-drug-kisqali/
Novartis HQ

News/ News/ Sales and Marketing

Novartis CEO thinks 2nd health lockdown unlikely, as Q3 sales stabilise

, , , , , , , 0 Comment

Novartis’ pharmaceutical sales recovered in the third quarter of this year after an earlier COVID-19 decline, as new

X
Novartis CEO thinks 2nd health lockdown unlikely, as Q3 sales stabilise
https://pharmaphorum.com/news/novartis-ceo-thinks-2nd-health-lockdown-unlikely-as-q3-sales-stabilise/

Login

CONTINUE TO SITE >
X
Close in 10 seconds